Point72 Asset Management’s Astria Therapeutics ATXS Stock Holding History

Point72 Asset Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-31,389	Closed	-$411K	–	3772
2025 Q4	$411K	Sell	31,389 -718,546	-96%	-$8.58M	﹤0.01%	3337
2025 Q3	$5.46M	Sell	749,935 -12,821	-2%	-$86.8K	0.01%	1032
2025 Q2	$4.09M	Buy	+762,756	New	+$3.7M	0.01%	1039
2023 Q1	–	Sell	-225,000	Closed	-$3.35M	–	2226
2022 Q4	$3.35M	Buy	+225,000	New	+$2.32M	0.01%	843

Point72 Asset Management's ATXS Position: Q1 2026 in Review

Point72 Asset Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 31,389 shares — an estimated $411K sold.

Point72 Asset Management first reported a position in ATXS in Q4 2022 and held it in 4 quarters. The position peaked at $5.46M in Q3 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Point72 Asset Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Point72 Asset Management sold 31,389 Astria Therapeutics shares in Q1 2026, an estimated $411K.
Point72 Asset Management first reported a position in Astria Therapeutics in Q4 2022 and held it in 4 quarters.
Point72 Asset Management's Astria Therapeutics position peaked at $5.46M in Q3 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.